S-OMZ powder for injection
Ferron Par Pharmaceuticals
Ingredients in every vial
| Esomeprazole | 40 mg |
Each package contains
Other details
| Flavour | None |
W.H.O. classification
| ATC Level 1 | A - Alimentary tract and metabolism |
| ATC Level 2 | A02 - Drugs for Acid Related Disorders |
| ATC Level 3 | A02A - Antacids |
Warnings
Pregnancy
Lactation
Alcohol
Machinery
Available in
 |
Cambodia |
Dosage information
18 YEARS OLD AND ABOVE
Gastric antisecretory treatment when the oral route is not possible.
Patients who cannot take oral medicines may be treated parenterally with 20-40 mg once daily.
Patients with reflux esophagitis should be treated with 40 mg once daily. Patients with symptomatically for reflux disease should be treated with 20 mg once daily.
For healing of gastric ulcers associated with NSAID therapy the usual dose is 20 mg once daily. Usually the IV treatment durations short and transfer to oral treatment should be made as soon as possible.
Maintenance of hemostasis and prevention of rebleeding of gastric and duodenal ulcers following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers, 80 mg should be administered as a bolus infusion over 30 minutes, followed by continuous intravenous infusion of 8 mg/hour given over 3 days (72 hours).
The parenteral treatment period should be followed by acid-suppression therapy with esomeprazole 40 mg gastro-resistant tablet once daily for 4 weeks
0 TO 18 YEARS OLD
Children and adolescent Esomeprazole IV should not be used in children and adolescent since no data is available.
IMPAIRED HEPATIC FUNCTION
Treatment for bleeding ulcer patients with severe liver impairment, following an initial bolus dose of 80 mg esomeprazole for infusion, a continuous intravenous infusion dose of 4 mg/hour for 71.5 hours may be sufficient.
Indication
Esomeprazole injection is indicated for:
– Gastric antisecretory treatment when the oral route is not possible, such as:
– Gastroesophageal reflux disease in patients with esophagitis and/or severe symptoms of reflux.
– Healing of gastric ulcers associated with NSAIDs therapy.
– The short term maintenance of hemostasis and prevention of rebleeding in patients following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers.